Karuna Therapeutics, Inc. which can be found using ticker (KRTX) have now 18 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 332 and 197 calculating the mean target price we have $271.11. Now with the previous closing price of $169.68 this indicates there is a potential upside of 59.8%. The day 50 moving average is $174.96 and the 200 day moving average is $195.44. The company has a market capitalization of 6.30B. The current share price for the company is: 167.3 USD
The potential market cap would be $10,068,878,047 based on the market consensus.
The company has a dividend yield of 2.93%. Other points of data to note are a P/E ratio of -, revenue per share of 0.17 and a -25.87% return on assets.
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline is primarily built on the therapeutic potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS), and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. The Company is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, as well as for the treatment of psychosis in Alzheimer’s disease (AD). The Company is also engaged in developing its investigational TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and plan to provide details regarding the expected development of KAR-2618.
